Acne vulgaris and bacterial skin infections: Review of the topical quinolone nadifloxacin

Expert Review of Dermatology

Volumn 1, Issue 5, 2006, Pages 643-654

  Nenoff, Pietro ^a  

^a Laboratorium fur Medizinische Mikrobiologie   (Germany)

Author keywords

acne vulgaris; bacterial skin infection; coagulase negative staphylococci; fluoroquinolone; methicillin resistant Staphylococcus aureus; minimum inhibitory concentration; nadifloxacin; Propionibacterium acnes; Staphylococcus aureus; streptococci; topical treatment

Indexed keywords

EID: 84975454322     PISSN: 17469872     EISSN: 17469880     Source Type: Journal    
DOI: 10.1586/17469872.1.5.643     Document Type: Article

References (62)

1. Leyden JJ. Current issues in antimicrobial therapy for the treatment of acne. J. Eur. Acad. Dermatol. Venereol. 15 (Suppl. 3), 51–55 (2001).
2. Vowels BR, Yang S, Leyden JJ. Induction of proinflammatory cytokines by a soluble factor of Propionibacterium acnes: implications for chronic inflammatory acne. Infect. Immun. 63, 3158–3165 (1995).
3. Gollnick HPM, Vogt K, Herrmann J et al. Topical quinolone OPC-7251, a clinical and microbiological study in acne. Eur. J. Dermatol. 4, 210–215 (1994).
4. William DJ. Acne. N. Engl. J. Med. 352, 1463–1472 (2005).
5. Cunliffe JC. Akne. Hippokrates Verlag Stuttgart, Germany (1993).
6. Leyden JJ. Antibiotic resistant acne. Cutis 17, 593–596 (1976).
7. Eady EA, Jones CE, Tipper JL, Cove JH, Cunliffe WJ, Layton AM. Antibiotic resistant propionibacteria in acne: need for policies to modify antibiotic usage. BMJ 306, 555–556 (1993).
8. Eady EA, Cove JH, Holland KT, Cunliffe WJ. Erythromycin resistant propionibacteria in antibiotic treated acne patients: association with therapeutic failure. Br. J. Dermatol. 121, 51–57 (1989).
9. Nenoff P, Haustein UF, Keller U. In vitro susceptibility of propionibacteria and staphylococci from acne patients to erythromycin. Eur. J. Acad. Dermatol. Venerol. 4, 181–182 (1995).
10. Patel MV, De Souza NJ, Gupte SV et al. Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models. Antimicrob. Agents Chemother. 48 (12), 4754–4761 (2004).
11. Souza NJ de, Gupte SV, Deshpande PK et al. A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus. J. Med. Chem. 48, 5232–5242 (2005).
12. Takahashi N, Shibahara T, Shiragiku T et al. Reduction of in vitro clastogenicity induced by the mixture of optical isomers of nadifloxacin during storage. Arzneimittelforschung 45, 195–197 (1995).
13. Suh B, Lorber B. Quinolones. Med. Clin. North Am. 79, 869–894 (1995).
14. Chu DT, Fernandes PB. Structure-activity relationships of the fluoroquinolones. Antimicrob. Agents Chemother. 33, 131–135 (1989).
15. Crumplin GC. Aspects of chemistry in the development of the 4-quinolone antibacterial agents. Rev. Inf. Dis. 10 (Suppl. 1), 2–9 (1988).
16. Domagala JM, Hanna LD, Heifetz CL et al. New structure-activity relationships of the quinolone antibacterials using the target enzymes. The development and application of a DNA gyrase assay. J. Med. Chem. 29, 394–404 (1986).
17. Oizumi N, Kawabata S, Hirao M et al. Relationship between mutations in the DNA gyrase and topoisomerase IV genes and nadifloxacin resistance in clinically isolated quinolone-resistant Staphylococcus aureus. J. Infect. Chemother. 7, 191–194 (2001).
18. Ishikawa H, Tabusa F, Miyamoto H et al. Studies on antibacterial agents. I. Synthesis of substituted 6,7-dihydro-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acids. Chem. Pharm. Bull (Tokyo) 37, 2103–2108 (1989).
19. Morita S, Otsubo K, Uchida M, Kawabata S, Tamaoka H, Shimizu T. Synthesis and antibacterial activity of the metabolites of 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidyl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid (OPC-7251). Chem. Pharm. Bull (Tokyo) 38, 2027–2029 (1990).
20. Kawabata S, Masada H, Wakebe H, Ohmori K, Tamaoka H. Bacteriological evaluation of OPC-7251, a new pyridone carboxylic acid antimicrobial agent. 2: therapeutic effect of OPC-7251 cream on experimental infection model in mice. Chemotherapy 37, 1179–1183 (1989).
21. Muto N, Mitoh Y, Yamamoto I. Development of a sensitive enzyme immunoassay for OPC-7251, a novel antimicrobial agent for percutaneous application. J. Immunoassay 11, 1–16 (1990).
22. Aoki M, Katoh H, Seki T et al. Thirteen-week percutaneous toxicity and four-week recovery tests of the antibacterial agent, (±)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidyl)-5-methyl-1-oxo-1 H, 5H-benzo[i, j]quinolizine-2-carboxylic acid (OPC-7251) in dogs. Iyakuhin Kenkyu 21, 1177–1202 (1990).
23. Kurokawa I, Akamatsu H, Nishijima S, Asada Y, Kawabata S. Clinical and bacteriological evaluation of OPC-7251 in patients with acne: a double-blind group comparison study versus cream base. J. Am. Acad. Dermatol. 25, 674–681 (1991).
24. Plewig G, Holland KT, Nenoff P. Clinical and bacteriological evaluation of nadifloxacin 1% cream in patients with acne vulgaris: a double-blind, phase III comparison study versus erythromycin 2% cream. Eur. J. Dermatol. 16 (1), 48–55 (2006).
25. Nadifloxacin in the treatment of acne vulgaris. Monography, Prous Science, Barcelona, Spain, 2005.
26. Bojar RA, Cunliffe WJ, Holland KT. The short-term treatment of acne vulgaris with benzoyl peroxide: Effects on the surface and follicular cutaneous microflora. Br. J. Dermatol. 132, 204–208 (1995).
27. Bojar RA, Hittel N, Cunliffe WJ, Holland KT. Direct analysis of resistance in cutaneous microflora during treatment of acne vulgaris with topical 1% nadifloxacin and 2% erythromycin. Drugs 49 (Suppl. 2), 164–167 (1995).
28. Gollnick H, Schramm M. Topical drug treatment in acne. Dermatology 196, 119–125 (1998).
29. Kawabata S, Ohguro K, Mukai F, Ohmori K, Miyamoto H, Tamaoka H. Bacteriological evaluation of OPC-7251, a new pyridone carboxylic acid antimicrobial agent. 1. In vitro antibacterial activity. Chemotherapy 37, 1160–1178 (1989).
30. Akamatsu H, Sasaki H, Kurokawa I, Nishijima S, Asada Y, Niwa Y. Effect of nadifloxacin on neutrophil functions. J. Int. Med. Res. 23 (1), 19–26 (1995).
31. Kuwahara K, Kitazawa T, Kitagaki H, Tsukamoto T, Kikuchi M. Nadifloxacin, an antiacne quinolone antimicrobial, inhibits the production of proinflammatory cytokines by human peripheral blood mononuclear cells and normal human keratinocytes. J. Dermatol. Sci. 38 (1), 47–55 (2005).
32. Murata K, Sugita K, Kobayashi M, Kabashima K, Tokura Y. Nadifloxacin downmodulates antigen-presenting functions of epidermal Langerhans cells and keratinocytes. J. Dermatol. Sci. 42, 91–99 (2006).
33. Inui S, Nakao T, Itami S. Modulation of androgen receptor transcriptional activity by anti-acne reagents. J. Dermatol. Sci. 36 (2), 97–101 (2004).
34. Vogt K, Herrmann J, Blume U et al. Comparative activity of the topical quinolone OPC-7251 against bacteria associated with acne vulgaris. Eur. J. Clin. Microbiol. Inf. Dis. 11, 943–945 (1992).
35. Vogt K, Hahn H, Herrmann J et al. Antimicrobial evaluation of nadifloxacin (OPC-7251), a new topical quinolone, in acne vulgaris. Drugs 49 (Suppl. 2), 266–268 (1995).
36. Nishijima S, Kurokawa I, Kawabata S. Sensitivity of Propionibacterium acnes isolated from acne patients: comparative study of antimicrobial agents. J. Int. Med. Res. 24, 473–477 (1996).
37. Nishijima S, Kurokawa I, Katoh N, Watanabe K. The bacteriology of acne vulgaris and antimicrobial susceptibility of Propionibacterium acnes and Staphylococcus epidermidis isolated from acne lesions. J. Dermatol. 27, 318–323 (2000).
38. Ross JI, Snelling AM, Eady EA et al. Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the USA, Japan and Australia. Br. J. Dermatol. 144, 339–346 (2001).
39. Nishijima S, Namura S, Akamatsu H et al. Activity of eight fluoroquinolones against both methicillin-susceptible and -resistant Staphylococcus aureus isolated from skin infections. J. Dermatol. 22, 153–155 (1995).
40. Nishijima S, Nakagawa M, Sugiyama T et al. Sensitivity of Staphylococcus aureus, isolated from skin infections in 1994, to 19 antimicrobial agents. J. Int. Med. Res. 23, 328–334 (1995).
41. Nishijima S, Nakagawa M, Tsuboi N et al. Activity of nadifloxacin against methicillin-resistant Staphylococcus aureus isolated from skin infections: comparative study with seven other fluoroquinolones. J. Int. Med. Res. 24, 12–16 (1996).
42. Nishijima S, Namura S, Kawai S, Akamatsu H, Asada Y, Kawabata S. Sensitivity of Staphylococcus aureus and Streptococcus pyogenes isolated from skin infections in 1992 to antimicrobial agents. J. Dermatol. 21 (4), 233–238 (1994).
43. Nishijima S, Nakagawa M. Sensitivity of antibacterials of Staphylococcus aureus isolated from impetigo patients. J. Int. Med. Res. 25, 210–213 (1997).
44. Haustein UF, Nenoff P, Hittel N. Topical quinolone nadifloxacin (OPC-7251): a clinical and microbiological multicenter study in bacterial skin infection. Skin Pharmacol. 9, 151 (1996) (Abstract).
45. Haustein UF, Nenoff P, Hittel N. Topical quinolone nadifloxacin (OPC-7251) in bacterial skin disease: clinical evaluation in multicenter open trial and in vitro antimicrobiological susceptibility testing. J. Dermatol. Treat. 8, 87–92 (1997).
46. Nishijima S, Kurokawa I, Nakaya H. Susceptibility change to antibiotics of Staphylococcus aureus strains isolated from skin infections between July 1994 and November 2000. J. Infect. Chemother. 8, 187–189 (2002).
47. Jones RN. Fluoroquinolone resistance. An evolving national problem or just a problem for some physicians? Diagn. Microbiol. Inf. Dis. 15, 177–179 (1991).
48. Raviglione MC, Boyle JF, Mariuz P, Pablos-Mendez A, Cotes H, Merlo A. Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in an acute-care hospital. Antimicrob. Agents Chemother. 34, 2050–2054 (1990).
49. Nenoff P, Haustein UF, Hittel N. Activity of nadifloxacin (OPC-7251) and seven other antimicrobial agents against aerobic and anaerobic Gram-positive bacteria isolated from bacterial skin infections. Chemotherapy 50, 196–201 (2004).
50. Hooper DC. Quinolone mode of action. Drugs 49 (Suppl. 2), 10–15 (1995).
51. Takei M, Fukuda H, Kishii R, Hosaka M. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob. Agents Chemother. 45, 3544–3547 (2001).
52. Eady EA, Gloor M, Leyden JJ. Propionibacterium acnes resistance: a worldwide problem. Dermatology 206, 54–56 (2003).
53. Jansen T, Körber A, Folkmann A, Grabbe S. Topical acne therapy with a combination of clindamycin 1% and benzoyl peroxide 5%. Akt Dermatol. 31, 566–571 (2005).
54. Worret WI, Fluhr JW. Acne therapy with topical benzoylperoxide, antibiotics and azelaic acid. JDDG 4, 293–300 (2006).
55. Simpson N. Antibiotics in acne: time for a rethink. Br. J. Dermatol. 144, 225–228 (2001).
56. Komagata Y, Komiyama K, Nomura S. Fundamental studies on antibacterial activity of clindamycin against Propionibacterium acnes. Jpn J. Antibiot. 51, 130–136 (1998).
57. Nenoff P, Haustein UF, Hittel N. Nadifloxacin (OPC-7251) in acne vulgaris: clinical evaluation and in vitro antibacterial activity. J. Invest. Dermatol. 108, 392 (1997).
58. Iwahara K, Ishii K, Chen Y, Miura Y. Tufted hair folliculitis: response to topical therapy with nadifloxacin. Eur. J. Dermatol. 9, 276–277 (1999).
59. Kimata H. Effect of nadifloxacin on atopic dermatitis with methicillin-resistant Staphylococcus aureus in young children. Eur. J. Pediatr. 158, 949 (1999).
60. Yamakawa T, Mitsuyama J, Hayashi K. In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J. Antimicrob. Chemother. 49, 455–465 (2002).
61. Leyden JJ. Topical treatment for acne vulgaris. N. Engl. J. Med. 336, 1156–1162 (1997).
62. Sisomicin cream vs nadifloxacin cream in primary pyodermas (Study P04460). Verified by Schering-Plough December 2005. www.clinicaltrials.gov